1. Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients.
- Author
-
Amaral NB, Rodrigues TS, Giannini MC, Lopes MI, Bonjorno LP, Menezes PISO, Dib SM, Gigante SLG, Benatti MN, Rezek UC, Emrich-Filho LL, Sousa BA, Almeida SCL, Luppino-Assad R, Veras FP, Schneider AH, Leiria LOS, Cunha LD, Alves-Filho JC, Cunha TM, Arruda E, Miranda CH, Pazin-Filho A, Auxiliadora-Martins M, Borges MC, Fonseca BAL, Bollela VR, Del-Ben CM, Cunha FQ, Santana RC, Vilar FC, Zamboni DS, Louzada-Junior P, and Oliveira RDR
- Subjects
- Humans, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Interleukin-18, NLR Proteins, Colchicine therapeutic use, Interleukin-1beta metabolism, Inflammasomes metabolism, COVID-19
- Abstract
Objective: To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19., Methods: We present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products-active caspase-1 (Casp1p20), IL-1β, and IL-18-were assessed at enrollment and after 48-72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days., Results: Thirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2-3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1β., Conclusion: Treatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the 'cytokine storm' in COVID-19., Trial Registration Numbers: RBR-8jyhxh., (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2023
- Full Text
- View/download PDF